One-year outcomes with the TAXUS liberté stent in the real world: The TAXUS OLYMPIA registry (Phase I)

Journal of Interventional Cardiology

Volumn 21, Issue 6, 2008, Pages 512-518

  Ahmed, Waqar Habib ^a   Zambahari, Robaayah ^b   Al Rashdan, Ibrahim ^c   Al Naeemi, Abdullah ^d   Saeed, Fuad A ^e   Mascioli, Stephen ^f  

^a The General Directorate of Armed Forces Health Services   (Saudi Arabia)

^b NATIONAL HEART INSTITUTE   (Malaysia)

^c Chest Diseases Hospital Kuwait   (Kuwait)

^d ZAYED MILITARY HOSPITAL   (United Arab Emirates)

^e BAHRAIN DEFENCE FORCE HOSPITAL   (Bahrain)

^f BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; ASIA; CENTRAL AMERICA; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE REGISTRY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; PRIORITY JOURNAL; REVASCULARIZATION; SOUTH AMERICA; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ANGIOPLASTY, BALLOON; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASIA; CENTRAL AMERICA; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HEART CATHETERIZATION; HUMANS; MALE; MIDDLE AGED; MIDDLE EAST; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; REGISTRIES; SOUTH AMERICA; TAXUS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 56549124630     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2008.00395.x     Document Type: Article

References (15)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002 346 : 1773 1780.
2. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003 108 : 788 794.
3. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003 349 : 1315 1323.
4. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation 2004 109 : 1942 1947.
5. Abizaid A, Chan C, Lim YT, et al. Twelve-month outcomes with a paclitaxel-eluting stent transitioning from controlled trials to clinical practice (the WISDOM Registry). Am J Cardiol 2006 98 : 1028 1032.
6. Niemelä K, Chevalier B, Stoerger H, et al. The TAXUS paclitaxel-eluting stent in high-risk patients: Global usage patterns and clinical outcomes in the "real-world" MILESTONE II registry. Transcatheter Cardiovascular Therapeutics. Washington, D.C., 2005.
7. Lasala J, Cox DA, Dobies D, et al. Usage patterns and 2-year outcomes with the TAXUS express stent: Results of the U.S. ARRIVE 1 Registry. Catheter Cardiovasc Interv. 2008 49 : 1676 1683.
8. Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: One-year follow-up of the e-Cypher registry. Circulation 2006 113 : 1434 1441.
9. Ahmed W. A global approach to drug-eluting stent registry design: The TAXUS OLYMPIA Registry. J Invasive Cardiol 2006 18 : 25 28.
10. Ahmed WH. Review of the TAXUS Liberte SR paclitaxel-eluting coronary stent. Expert Rev Med Devices 2007 4 : 117 120.
11. Turco MA, Ormiston JA, Popma JJ, et al. Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: The pivotal TAXUS ATLAS trial. J Am Coll Cardiol 2007 49 : 1676 1683.
12. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007 297 : 1992 2000.
13. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007 297 : 2001 2009.
14. Ellis SG, Colombo A, Grube E, et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: A TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 2007 49 : 1043 1051.
15. Pinto DS, Stone GW, Ellis SG, et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: Results from the TAXUS-IV trial. J Am Coll Cardiol 2006 48 : 32 36.